Molecular and Translational Oncology Research

分子和转化肿瘤学研究

• 批准号: 10202497
• 负责人: JOHN BLENIS
• 金额: $ 28.53万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-01 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10202497
• 关键词: Molecular; Oncology; Research

ABSTRACT The past decade, an explosion of research and technological achievements in molecular oncology and genomics have offered an unprecedented opportunity to transform patient care. This shift in the traditional cancer research paradigm, demands for more sophisticated skills to be acquired by cancer scientists. We are requesting support via a new T32 training grant for the research training of four postdoctoral fellows in Molecular and Translational Oncology Research (MTOR) at Weill Cornell Medicine (WCM). WCM will provide funding for an additional fifth training slot. The objective of this program is to recruit the best possible candidates with a solid foundation in basic science and train them in molecular and translational oncology so that they can apply their knowledge to address important clinically unmet needs in the prevention, diagnosis, and treatment of cancer patients. MTOR trainees will receive program support for two years during which they will follow a structured and rigorous postdoctoral training path. The MTOR program is a joint effort of 17 outstanding WCM preceptors and co-mentors, and a dense network of clinical collaborators, who are international leaders in their respective fields. Trainees will further profit from the leveraging of institutional resources such as the Sandra and Edward Meyer Cancer Center and Weill Cornell's Clinical and Translational Science Center (CTSC). MTOR's highly personalized training plan will include 1) individual development plans and customized workplans; 2) rigorous translationally focused research training; 3) hands-on experience in cutting-edge methodologies; and 4) a comprehensive curriculum of innovative core and ancillary skill acquisition workshops, including writing, leadership, communication, and entrepreneurial perspectives. We anticipate a pool of at least 300 candidates. We have assembled an outstanding roster of external and internal advisory committee members with the mandate to evaluate the program and provide specific recommendations to improve its efficiency. MTOR has a strong diversity focus and through its rigorous, structured and highly personalized curriculum, seeks to train the future leaders in translational cancer research in the USA.

抽象的 过去的十年，分子肿瘤学和基因组学的研究和技术成就的爆炸已经爆炸 为改变患者护理提供了前所未有的机会。传统癌症研究范式的这种转变， 对癌症科学家获得更复杂技能的需求。我们正在通过新的T32要求支持 分子和转化肿瘤研究中四名博士后研究员的研究培训培训培训 （MTOR）在Weill Cornell Medicine（WCM）。 WCM将为额外的第五个培训插槽提供资金。这 该计划的目的是招募基础科学领域扎实的基础和训练的最佳候选人 它们在分子和翻译肿瘤学中，以便他们可以运用自己的知识来在临床上解决重要的问题 癌症患者的预防，诊断和治疗中未满足的需求。 MTOR学员将收到计划 支持两年，在此期间，他们将遵循结构化和严格的博士后训练路径。 mtor 计划是17个出色的WCM主管和同事的共同努力，以及密集的临床网络 合作者，他们是各自领域的国际领导人。受训者将从杠杆上进一步获利 桑德拉（Sandra）和爱德华·迈耶（Edward Meyer）癌症中心和威尔·康奈尔（Weill Cornell）的临床和机构资源 翻译科学中心（CTSC）。 MTOR高度个性化的培训计划将包括1）个人 开发计划和定制工作计划； 2）严格以翻译为中心的研究培训； 3）动手 尖端方法论的经验； 4）创新核心和辅助技能的全面课程 收购讲习班，包括写作，领导力，交流和企业家观点。我们期待 至少有300名候选人的池。我们组成了外部和内部咨询委员会的出色名册 具有评估该计划并提供具体建议以提高其效率的成员。 MTOR具有强大的多样性重点，并且通过其严格，结构化和高度个性化的课程，他们试图寻求 培训美国转化癌研究的未来领导者。

项目成果

System-wide transcriptome damage and tissue identity loss in COVID-19 patients.

• DOI: 10.1016/j.xcrm.2022.100522
• 发表时间: 2022-02-15
• 期刊: Cell reports. Medicine
• 作者: Park J;Foox J;Hether T;Danko DC;Warren S;Kim Y;Reeves J;Butler DJ;Mozsary C;Rosiene J;Shaiber A;Afshin EE;MacKay M;Rendeiro AF;Bram Y;Chandar V;Geiger H;Craney A;Velu P;Melnick AM;Hajirasouliha I;Beheshti A;Taylor D;Saravia-Butler A;Singh U;Wurtele ES;Schisler J;Fennessey S;Corvelo A;Zody MC;Germer S;Salvatore S;Levy S;Wu S;Tatonetti NP;Shapira S;Salvatore M;Westblade LF;Cushing M;Rennert H;Kriegel AJ;Elemento O;Imielinski M;Rice CM;Borczuk AC;Meydan C;Schwartz RE;Mason CE
• 通讯作者: Mason CE

The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases.

• DOI: 10.1126/sciadv.abg1964
• 发表时间: 2021-11-05
• 期刊: Science advances
• 影响因子: 13.6
• 作者: Marullo R;Castro M;Yomtoubian S;Calvo-Vidal MN;Revuelta MV;Krumsiek J;Cho A;Morgado PC;Yang S;Medina V;Roth BM;Bonomi M;Keshari KR;Mittal V;Navigante A;Cerchietti L
• 通讯作者: Cerchietti L

Lineage Reversion Drives WNT Independence in Intestinal Cancer.

• DOI: 10.1158/2159-8290.cd-19-1536
• 发表时间: 2020-10
• 期刊: Cancer discovery
• 影响因子: 28.2
• 作者: Han T;Goswami S;Hu Y;Tang F;Zafra MP;Murphy C;Cao Z;Poirier JT;Khurana E;Elemento O;Hechtman JF;Ganesh K;Yaeger R;Dow LE
• 通讯作者: Dow LE

Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.

• DOI: 10.1038/s41467-021-23780-y
• 发表时间: 2021-06-07
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Brady NJ;Bagadion AM;Singh R;Conteduca V;Van Emmenis L;Arceci E;Pakula H;Carelli R;Khani F;Bakht M;Sigouros M;Bareja R;Sboner A;Elemento O;Tagawa S;Nanus DM;Loda M;Beltran H;Robinson B;Rickman DS
• 通讯作者: Rickman DS

The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.

通过基因组转录组和单细胞蛋白标记物分析转移性上尿路上皮癌的演变。

• DOI: 10.1038/s41467-024-46320-w
• 发表时间: 2024
• 期刊: Nature communications
• 影响因子: 16.6
• 作者: Ohara,Kentaro;Rendeiro,AndréFigueiredo;Bhinder,Bhavneet;Eng,KennethWha;Ravichandran,Hiranmayi;Nguyen,Duy;Pisapia,David;Vosoughi,Aram;Fernandez,Evan;Shohdy,KyrillusS;Manohar,Jyothi;Beg,Shaham;Wilkes,David;Robinson,BrianD;Kha
• 通讯作者: Kha